Lunai Bioworks (NASDAQ:LNAI) Releases Quarterly Earnings Results

Lunai Bioworks (NASDAQ:LNAI) issued its quarterly earnings results on Friday. The company reported $0.13 earnings per share for the quarter, Zacks reports.

Lunai Bioworks Stock Up 2.9%

Shares of LNAI traded up $0.03 during mid-day trading on Friday, hitting $1.06. 593,767 shares of the company traded hands, compared to its average volume of 8,996,835. The stock has a market capitalization of $24.57 million, a price-to-earnings ratio of -0.14 and a beta of 0.31. Lunai Bioworks has a 1 year low of $0.81 and a 1 year high of $21.00.

Analyst Upgrades and Downgrades

LNAI has been the topic of several recent analyst reports. Weiss Ratings assumed coverage on shares of Lunai Bioworks in a research report on Wednesday, October 8th. They set a “sell (e+)” rating on the stock. Wall Street Zen cut shares of Lunai Bioworks to a “strong sell” rating in a report on Friday, October 3rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase.